Barclays Maintains Equal-Weight on Revvity, Raises Price Target to $160
10/7/2026
Impact: 50
Healthcare
Barclays analyst Luke Sergott has maintained an Equal-Weight rating on Revvity (NYSE: RVTY) while raising the price target from $115 to $160. This adjustment reflects a positive outlook on the company's performance.
AI summary, not financial advice
Share: